Patent · US Active

Prodrugs activated by plasmin and their use in cancer chemotherapy

US7893023B2 · kind B2 · utility

16Cited by

2References

37Claims

0Family size

Assignee

MEDAREX INC. · US

Inventors

Andre Trouet · Winksele, BE
Vincent Dubois · Ittre, BE
Alexandre Passioukov · Brussels, BE

Key dates

Filing date	Jun 11, 2008
Grant date	Feb 22, 2011
Priority date	—
Expiry date	Jun 11, 2028

Classification

Technology area (CPC B)Performing Operations; Transporting
CPC primaryB82Y5/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.